Mary E Aronow1, Allan K Topham2, Arun D Singh3. 1. Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2. Coalition of National Cancer Cooperative Group Inc., Philadelphia, PA, USA. 3. Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA.
Abstract
PURPOSE: To analyze trends in incidence, treatment, and survival of uveal melanoma in the United States from 1973 to 2013 using the Surveillance, Epidemiology, and End Results database. MATERIALS AND METHODS: Patients were identified using International Classification of Disease for Oncology codes: C69.3 (choroid), C69.4 (ciliary body and iris), and C69.2 (retina). Trends in age-adjusted incidence, treatment (surgery or radiation), and 5-year relative survival were calculated. RESULTS: There were 4,999 cases of uveal melanoma. The majority (97.8%) were reported by hospital inpatient/outpatient clinics. Histopathologic confirmation was available in 67.8%. The mean age-adjusted incidence was 5.2 per million (95% CI 5.0-5.4). When the incidence was standardized for race, a small but statistically significant (p < 0.05) annual percentage change of 0.5% was detected in Whites. There was a decline in patients treated with surgery alone (94.2% from 1973 to 1975 vs. 24.7% from 2012 to 2013). A corresponding increase was observed in radiation as primary treatment selection (1.3% from 1973 to 1975 vs. 68.3% from 2012 to 2013). No change in the 5-year relative survival (80.9%) was observed. CONCLUSIONS: The age-adjusted incidence of uveal melanoma has remained stable with a minor increase in Whites. Despite a shift towards globe-preserving treatment, there has not been a concomitant improvement in survival.
PURPOSE: To analyze trends in incidence, treatment, and survival of uveal melanoma in the United States from 1973 to 2013 using the Surveillance, Epidemiology, and End Results database. MATERIALS AND METHODS: Patients were identified using International Classification of Disease for Oncology codes: C69.3 (choroid), C69.4 (ciliary body and iris), and C69.2 (retina). Trends in age-adjusted incidence, treatment (surgery or radiation), and 5-year relative survival were calculated. RESULTS: There were 4,999 cases of uveal melanoma. The majority (97.8%) were reported by hospital inpatient/outpatient clinics. Histopathologic confirmation was available in 67.8%. The mean age-adjusted incidence was 5.2 per million (95% CI 5.0-5.4). When the incidence was standardized for race, a small but statistically significant (p < 0.05) annual percentage change of 0.5% was detected in Whites. There was a decline in patients treated with surgery alone (94.2% from 1973 to 1975 vs. 24.7% from 2012 to 2013). A corresponding increase was observed in radiation as primary treatment selection (1.3% from 1973 to 1975 vs. 68.3% from 2012 to 2013). No change in the 5-year relative survival (80.9%) was observed. CONCLUSIONS: The age-adjusted incidence of uveal melanoma has remained stable with a minor increase in Whites. Despite a shift towards globe-preserving treatment, there has not been a concomitant improvement in survival.
Authors: Arun D Singh; Carlos A Medina; Nakul Singh; Mary E Aronow; Charles V Biscotti; Pierre L Triozzi Journal: Br J Ophthalmol Date: 2015-07-31 Impact factor: 4.638
Authors: Hima Anbunathan; Ruth Verstraten; Arun D Singh; J William Harbour; Anne M Bowcock Journal: Clin Cancer Res Date: 2019-06-21 Impact factor: 12.531
Authors: Carin F Gonsalves; David J Eschelman; Robert D Adamo; P Rani Anne; Marlana M Orloff; Mizue Terai; Anthony N Hage; Misung Yi; Inna Chervoneva; Takami Sato Journal: Radiology Date: 2019-08-27 Impact factor: 11.105